| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.25▼ | 5.27▼ | 5.28▼ | 4.86▲ | 4.72▲ |
| MA10 | 5.27▼ | 5.29▼ | 5.23▼ | 4.82▲ | 4.18▲ |
| MA20 | 5.28▼ | 5.18▲ | 4.99▲ | 4.67▲ | 3.57▲ |
| MA50 | 5.17▲ | 4.88▲ | 4.83▲ | 4.09▲ | 2.34▲ |
| MA100 | 4.94▲ | 4.83▲ | 4.85▲ | 3.47▲ | 2.33▲ |
| MA200 | 4.83▲ | 4.68▲ | 4.22▲ | 2.46▲ | 2.49▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.017▼ | -0.010▼ | 0.022▲ | -0.001▼ | 0.145▲ |
| RSI | 48.267▼ | 61.067▲ | 64.778▲ | 65.727▲ | 73.081▲ |
| STOCH | 2.941▼ | 62.443 | 78.508 | 45.207 | 64.771 |
| WILL %R | -87.500▼ | -39.706 | -29.348 | -23.469▲ | -8.657▲ |
| CCI | -219.444▼ | 5.264 | 41.603 | 123.115▲ | 121.983▲ |
|
Monday, December 08, 2025 03:49 AM
Cellectis SA ( ($CLLS) ) just unveiled an announcement. On December 8, 2025, Cellectis announced promising results from its Phase 1 NATHALI-01 ...
|
|
Sunday, December 07, 2025 10:40 PM
Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion ...
|
|
Sunday, December 07, 2025 09:32 PM
Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/12/25 | 5.15 | 5.45 | 5.15 | 5.22 | 219,268 |
| 10/12/25 | 4.72 | 5.13 | 4.72 | 5.13 | 223,162 |
| 09/12/25 | 4.61 | 4.655 | 4.47 | 4.59 | 87,844 |
| 08/12/25 | 4.74 | 4.899 | 4.57 | 4.62 | 61,651 |
| 05/12/25 | 4.77 | 4.8799 | 4.61 | 4.74 | 63,178 |
| 04/12/25 | 4.54 | 4.9177 | 4.54 | 4.83 | 76,630 |
| 03/12/25 | 4.73 | 4.75 | 4.52 | 4.66 | 52,670 |
| 02/12/25 | 4.74 | 4.77 | 4.6098 | 4.71 | 96,708 |
| 01/12/25 | 4.90 | 4.90 | 4.5186 | 4.67 | 135,019 |
| 28/11/25 | 5.03 | 5.11 | 4.95 | 5.07 | 47,045 |
|
|
||||
|
|
||||
|
|